Clover Biopharmaceuticals is a global commercial-stage biotechnology company that develops innovative vaccines. Self-described to be committed to improving health worldwide.

Clover Biopharmaceuticals

Clover Biopharmaceuticals | 7,293 followers on LinkedIn. Unleashing the power of innovative vaccines to save lives and improve health around the world | Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals

Jeff Farrow

Senior Director Clinical Operation at Clover Biopharmaceuticals

Aurore Dujardin

Founder， Chairman of the Board of Clover Biopharmaceuticals

Peng Liang

Building Around Talent

Oscar Shen

Attend Europe’s Largest Vaccine R&D Conference！ ☘️☘️☘️ WE ARE ATTENDING AND PRESENTING! ☘️☘️☘️ 📍WORLD VACCINE CONGRESS MEET YOU THERE! #WVC #CLOVER #Vaccine #RSV

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Euro

DNSSEC

Content Delivery Network

Global Site Tag

Mobile Non Scaleable Content

reCAPTCHA

jsDelivr

Business Management

Alan Liss

Founder

Senior Vice President, Global Clinical Development

Igor Smolenov

Vice President Clinical Operations/Medical Affairs-Vaccines

Vincent Mwangi

Executive Director, Corporate Communications

Albert Liao

Operations

Senior Director, Product Development and Portfolio Management

Chuan Wang

Executive Director, Vaccine Global Program

David Karaolis, PhD

Feng (Faith) Gao

Hui Cui

Thomas Leggett

Aileen Wang

Chief Financial Officer

Chris Wallace

Senior Vice President of Supply Chain

Xiaodong Wang

Director

Joshua Liang

Zheng Ping

David He

Jianwei Zhu

China Companies With More Than $1M in Revenue (Top 10K)

Clinical Trials Companies With Less Than $500M in Revenue

Companies With More Than 500 Employees (Top 10K)

Clinical Trials Companies With More Than 50 Employees

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Coalition for Epidemic Preparedness Innovations

Post-IPO Equity - Clover Biopharmaceuticals

GL Ventures LLC

Temasek Holdings

Series C - Clover Biopharmaceuticals

Series B - Clover Biopharmaceuticals

Delos Capital

Lapam Capital

Tianhe Life Sciences Venture Fund

Series A - Clover Biopharmaceuticals

Chengdu

Sichuan

China

Asia

China's Clover begins human trials of COVID-19 shot with GSK, Dynavax boosters

Clover Biopharmaceuticals Posts FY Loss RMB138.5 Mln

Global Oligonucleotide API Industry Poised for a Remarkable ...

Covid-19 Vaccine Market Share, Size and Forecast to 2031

Despite Recent Gains, Clover Biopharmaceuticals Insiders Are Still Down CN¥794k

COVID-19 Recombinant Protein Vaccine Industry Size ...

Clover Announces Executive Leadership Appointments

A COVID-19 vaccine developed using the Trimer-Tag technology platform, combined with Dynavax's CpG 1018 adjuvant and alum. It has shown efficacy against severe COVID-19 and variants.

A XBB-Adapted SARS-CoV-2 vaccine candidate, utilizing the Trimer-Tag technology for development, currently under regulatory review in China.

An RSV vaccine candidate based on stabilized PreF protein, leveraging the Trimer-Tag platform. It is in Phase I clinical trial.

A rabies vaccine candidate in development, utilizing the Trimer-Tag technology platform.

A treatment for chemotherapy-induced thrombocytopenia (CIT), currently showing positive Phase I results.

A trimeric fusion protein targeting intracavitary malignancies such as malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis.

Macao

India

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

news impact assignment basic	general
public peers	general	Nov 16, 2024 8:36 PM	63f8e67a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 8:36 PM	5b818f9d
crunchbase trigger	general	Nov 16, 2024 8:36 PM	d7ad363e
crunchbase profile	general	Nov 16, 2024 8:44 PM	be338d38
li profile	general	Nov 16, 2024 8:36 PM	54fcc7ff
translate crunchbase fundingrounds	general	Nov 16, 2024 9:10 PM	625d0eff
peers	general	Nov 16, 2024 8:36 PM	212506c7
news basic	general	Nov 16, 2024 8:36 PM	e52ba5a2
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

2197

COM:CLOVERBIOPHARMA

Clover Biopharmaceuticals

Last Close

0.29

22/11 07:42

Market Cap

415.27M

Beta: -

Volume Today

981K

Avg: -